Carbohydrate Antigen-125
Background: Carbohydrate antigen-125 (also known as cancer antigen-125) (CA-125) is a biomarker used to monitor for endometrial cancer progression, but it may also reflect other disease processes. Case Summary: A 70-year-old woman with metastatic endometrial cancer who was treated with paclitaxel, c...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | JACC: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666084925006448 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850086712983683072 |
|---|---|
| author | Vijay U. Rao, MD, PhD Thomas Fretz, MD Tina Ayeni, MD Kerry Skurka, BSN Meghana Raghavendra, MD Ankur Kalra, MD, MS |
| author_facet | Vijay U. Rao, MD, PhD Thomas Fretz, MD Tina Ayeni, MD Kerry Skurka, BSN Meghana Raghavendra, MD Ankur Kalra, MD, MS |
| author_sort | Vijay U. Rao, MD, PhD |
| collection | DOAJ |
| description | Background: Carbohydrate antigen-125 (also known as cancer antigen-125) (CA-125) is a biomarker used to monitor for endometrial cancer progression, but it may also reflect other disease processes. Case Summary: A 70-year-old woman with metastatic endometrial cancer who was treated with paclitaxel, carboplatin, and pembrolizumab presented with new onset ascites and rising CA-125 levels concerning for cancer progression. She received a diagnosis of heart failure (HF) and normalized her CA-125 levels with loop diuretic agents without changing her oncologic treatment. Discussion: CA-125 is a novel biomarker for HF monitoring because it correlates with increased intracardiac filling pressures. In this patient, concomitant endometrial malignant disease and HF complicated ascertainment of ascites and elevated biomarker origin. Therefore, clinicians should consider alternate causes of elevated CA-125 levels besides cancer progression. Take-Home Message: CA-125 levels in patients with endometrial cancer may not always reflect cancer disease progression because levels can be influenced by the presence of HF. |
| format | Article |
| id | doaj-art-dfc2f04afc884ea8ac57f3acbf0e524b |
| institution | DOAJ |
| issn | 2666-0849 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JACC: Case Reports |
| spelling | doaj-art-dfc2f04afc884ea8ac57f3acbf0e524b2025-08-20T02:43:24ZengElsevierJACC: Case Reports2666-08492025-07-01301710386610.1016/j.jaccas.2025.103866Carbohydrate Antigen-125Vijay U. Rao, MD, PhD0Thomas Fretz, MD1Tina Ayeni, MD2Kerry Skurka, BSN3Meghana Raghavendra, MD4Ankur Kalra, MD, MS5Indiana Heart Physicians, Franciscan Cardio-Oncology Center, Franciscan Health, Indianapolis, Indiana, USA; Address for correspondence: Dr Vijay U. Rao, Indiana Heart Physicians, 5330 East Stop 11 Road, Indianapolis, Indiana 46237, USA.Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USADepartment of Gynecologic Oncology, Franciscan Cardio-Oncology Center, Franciscan Health, Indianapolis, Indiana, USACardio-Oncology Program, Franciscan Cardio-Oncology Center, Franciscan Health, Indianapolis, Indiana, USADepartment of Oncology and Hematology, Franciscan Cardio-Oncology Center, Franciscan Health, Indianapolis, Indiana, USADepartment of Cardiovascular Medicine, Franciscan Health, Lafayette, Indiana, USA; Krannert Cardiovascular Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USABackground: Carbohydrate antigen-125 (also known as cancer antigen-125) (CA-125) is a biomarker used to monitor for endometrial cancer progression, but it may also reflect other disease processes. Case Summary: A 70-year-old woman with metastatic endometrial cancer who was treated with paclitaxel, carboplatin, and pembrolizumab presented with new onset ascites and rising CA-125 levels concerning for cancer progression. She received a diagnosis of heart failure (HF) and normalized her CA-125 levels with loop diuretic agents without changing her oncologic treatment. Discussion: CA-125 is a novel biomarker for HF monitoring because it correlates with increased intracardiac filling pressures. In this patient, concomitant endometrial malignant disease and HF complicated ascertainment of ascites and elevated biomarker origin. Therefore, clinicians should consider alternate causes of elevated CA-125 levels besides cancer progression. Take-Home Message: CA-125 levels in patients with endometrial cancer may not always reflect cancer disease progression because levels can be influenced by the presence of HF.http://www.sciencedirect.com/science/article/pii/S2666084925006448biomarkercarbohydrate antigen-125diuresisheart failure |
| spellingShingle | Vijay U. Rao, MD, PhD Thomas Fretz, MD Tina Ayeni, MD Kerry Skurka, BSN Meghana Raghavendra, MD Ankur Kalra, MD, MS Carbohydrate Antigen-125 JACC: Case Reports biomarker carbohydrate antigen-125 diuresis heart failure |
| title | Carbohydrate Antigen-125 |
| title_full | Carbohydrate Antigen-125 |
| title_fullStr | Carbohydrate Antigen-125 |
| title_full_unstemmed | Carbohydrate Antigen-125 |
| title_short | Carbohydrate Antigen-125 |
| title_sort | carbohydrate antigen 125 |
| topic | biomarker carbohydrate antigen-125 diuresis heart failure |
| url | http://www.sciencedirect.com/science/article/pii/S2666084925006448 |
| work_keys_str_mv | AT vijayuraomdphd carbohydrateantigen125 AT thomasfretzmd carbohydrateantigen125 AT tinaayenimd carbohydrateantigen125 AT kerryskurkabsn carbohydrateantigen125 AT meghanaraghavendramd carbohydrateantigen125 AT ankurkalramdms carbohydrateantigen125 |